PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 199 filers reported holding PDL BIOPHARMA INC in Q3 2016. The put-call ratio across all filers is 1.13 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $783,000 | -55.9% | 303,534 | -63.1% | 0.00% | -50.0% |
| Q1 2017 | $1,776,000 | +536.6% | 822,592 | +525.9% | 0.00% | +100.0% |
| Q4 2016 | $279,000 | -43.4% | 131,433 | -10.8% | 0.00% | 0.0% |
| Q3 2016 | $493,000 | -27.0% | 147,281 | -31.5% | 0.00% | 0.0% |
| Q2 2016 | $675,000 | -20.2% | 214,879 | -19.5% | 0.00% | -50.0% |
| Q1 2016 | $846,000 | -98.7% | 266,935 | -96.9% | 0.00% | -98.5% |
| Q4 2014 | $66,959,000 | -99.9% | 8,684,695 | -0.4% | 0.13% | +50.6% |
| Q3 2014 | $65,154,797,000 | -22.9% | 8,722,195 | -0.1% | 0.09% | -17.1% |
| Q2 2014 | $84,498,075,000 | +15.6% | 8,729,140 | -0.8% | 0.10% | +28.0% |
| Q1 2014 | $73,103,402,000 | +69.1% | 8,797,040 | +71.8% | 0.08% | +51.9% |
| Q4 2013 | $43,222,658,000 | +27.0% | 5,121,168 | +20.0% | 0.05% | -34.9% |
| Q3 2013 | $34,020,487,000 | +27.2% | 4,268,568 | +23.2% | 0.08% | +16.9% |
| Q2 2013 | $26,737,201,000 | – | 3,463,368 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DENALI ADVISORS LLC | 265,730 | $2,572,000 | 0.70% |
| Global X Management CO LLC | 1,160,576 | $11,234,000 | 0.65% |
| Advisors Asset Management, Inc. | 4,727,365 | $45,761,000 | 0.63% |
| Spark Investment Management LLC | 436,800 | $4,219,000 | 0.63% |
| LINDEN ADVISORS LP | 183,836 | $1,780,000 | 0.39% |
| Blue Fin Capital, Inc. | 46,361 | $449,000 | 0.36% |
| Atria Investments, Inc | 356,359 | $3,450,000 | 0.34% |
| QS Investors, LLC | 1,326,900 | $12,844,000 | 0.34% |
| BURNEY CO/ | 392,470 | $3,799,000 | 0.33% |
| Calvert Investment Management, Inc. | 506,662 | $4,904,000 | 0.33% |